What does the analysis imply about Beclin-1's prognostic value when dermal vs subcutaneous tumors are analyzed separately?

What does the analysis imply about Beclin-1's prognostic value when dermal vs subcutaneous tumors are analyzed separately?

• A. It becomes more predictive
• B. It becomes less predictive
• C. It remains non-predictive
• D. It reverses prognosis

Answer: (C)

When you test a biomarker's prognostic value, you want to see if the association with outcome appears in subgroups. Here, analyzing Beclin-1 separately in dermal and subcutaneous tumors does not reveal a significant link to outcomes in either group. Hazard ratios are around 1.0, confidence intervals cross 1, and p-values are not significant in both analyses. That means there’s no prognostic signal that Beclin-1 provides in dermal or subcutaneous tumors when evaluated alone, so its prognostic value remains non-predictive. It doesn’t become more predictive, nor less predictive, nor does it reverse prognosis in these subgroups.

When you test a biomarker's prognostic value, you want to see if the association with outcome appears in subgroups. Here, analyzing Beclin-1 separately in dermal and subcutaneous tumors does not reveal a significant link to outcomes in either group. Hazard ratios are around 1.0, confidence intervals cross 1, and p-values are not significant in both analyses. That means there’s no prognostic signal that Beclin-1 provides in dermal or subcutaneous tumors when evaluated alone, so its prognostic value remains non-predictive. It doesn’t become more predictive, nor less predictive, nor does it reverse prognosis in these subgroups.